Journal of Obesity Management

Journal of Obesity Management

Journal of Obesity Management

Current Issue Volume No: 1 Issue No: 1

Review Article Open Access Available online freely Peer Reviewed Citation

Obesity in Schizophrenia

1Professor Emerita, Department of Psychiatry, University of Toronto, 260 Heath Street W. Toronto, Ontario, Canada M5P 3L6.


Over the last three decades, an epidemic of obesity has markedly affected patients suffering from mental illnesses such as schizophrenia. Antipsychotic medications used to treat schizophrenia are considered as major culprits. The aim of this review is to first consider risk factors, to then outline negative sequelae of obesity for this population, and finally to address timing and content of recommended clinical interventions. Medical databases were searched with the terms “”weight,” “obesity,” and “schizophrenia.” Selection of articles was guided by date of publication; recent papers are preferentially cited. The main findings were that, in addition to antipsychotic medications, socio-economics, lifestyle, immune factors, and circadian rhythms also contribute to obesity risk. A barrier to effective health promotion within psychiatry has been the concern that fears about gaining weight might stop individuals with schizophrenia from taking needed antipsychotic medication. Recommendations, therefore, are to keep the dose of antipsychotic medication as low as possible, avoid polypharmacy, encourage healthy eating and physical activity, address sleep problems and substance use, monitor weight, blood pressure, and metabolic parameters regularly, utilize motivational interviewing techniques and peer support, pay special attention to special needs such as those of women during pregnancy, and include bariatric surgery as a potential intervention. Conclusion: Besides careful attention to medication regimens, the literature supports the active encouragement and support of patient self-management strategies to both prevent and manage obesity in schizophrenia.

Author Contributions
Received 21 Apr 2016; Accepted 23 May 2016; Published 28 May 2016;

Academic Editor: Bin Feng, Huazhong Agricultural University, Wuhan, China, Brown University, Rhode Island

Checked for plagiarism: Yes

Review by: Single-blind

Copyright ©  2016 Mary V. Seeman, et al

Creative Commons License     This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing interests

The authors have declared that no competing interests exist.


Mary V. Seeman (2016) Obesity in Schizophrenia. Journal of Obesity Management - 1(1):10-24.

Download as RIS, BibTeX, Text (Include abstract )

DOI 10.14302/issn.2574-450X.jom-16-1039


Historically, schizophrenia, the diagnostic term for a severe, but treatable, brain disorder that affects 1% of the world’s population and is characterized by hallucinations, delusions, disordered thinking, apathy, and cognitive deterioration, has always been linked to an asthenic (slender) body build 1. As a recent example, in a population-based cohort study of men born in Sweden between 1952 and 1982, those who subsequently developed schizophrenia had an initially lower body mass index than their peers. In fact, the men who were underweight (under 18.5 BMI) had a 30% increased risk of developing schizophrenia compared to their peers 2. And yet, today, in developed countries, schizophrenia has become closely associated with obesity, most markedly so since the 1990s, the time at which second-generation antipsychotic drugs became available 3. When I began my psychiatric residency in 1960 (chlorpromazine, the first 1st generation antipsychotic, coming on the market in 1952 in Europe) 4, essentially all my patients were thin. Today, most are portly. What has happened in the interim is greater availability and affordability of high calorie food as well as the advent of second generation antipsychotics to treat schizophrenia. While both first and second generations of antipsychotic agents exert their antipsychotic effect through dopamine D2 receptors, second generation drugs have a relatively stronger effect on insulin resistance and body weight because of their more potent actions on histamine and serotonin receptors, as well as on the muscarinic acetylcholine receptor and the adrenoreceptor 5.

This narrative review of the recent literature is intended as a brief consideration of drug and other risk factors for obesity in the schizophrenia population, illustrated with case examples, and ending with recommendations for prevention and comprehensive clinical management.


The multidisciplinary Google Scholar database was searched with the terms “”weight,” “obesity,” and “schizophrenia.” The literature on this topic is voluminous. Selection of articles was guided by date of publication; recent papers are preferentially cited.


Individuals diagnosed with schizophrenia have a 2.8 to 3.5 increased likelihood over that of the general population of being obese (body mass index of 30 or higher) 6. Both women and men with schizophrenia develop a central form of obesity with enlarged waist circumferences 7.

Obesity Risk Factors in Schizophrenia


Because the spike in obesity in this population correlates in time with the introduction of second-generation antipsychotic drugs, these agents are rightly considered to be major causal contributors to the phenomenon. During the same time period, however, obesity rates also rose in the general population not because of drugs but because of the proliferation and ready availability of calorie-rich foods and an increasingly sedentary urban lifestyle 8, 9. The Noncommunicable Disease 10 Risk Factor Collaboration of the World Health Organization pooled 1698 population-based studies consisting of more than 19 million participants and found that, from 1975 to 2014, the age-corrected mean body mass index (BMI) rose from 21.7 to 24.2 in men, with a slightly lesser rise in women. There are approximately 8% more obese individuals in the world today than there were 40 years ago 10. Although many of the very poor across the world continue to be undernourished, obesity is prevalent even among this demographic because healthy foods cost more than calorie-rich food. This is very relevant to individuals with schizophrenia who are among the poorest poor – due to several well-known factors such as the severity and chronicity of the symptoms (false perceptions, false beliefs, lack of motivation, cognitive defects) associated with this illness, the unemployment that results from both illness and interrupted schooling, and the direct costs of the illness, its treatment, and its long years of rehabilitation 11. Over the years of illness, people with schizophrenia drift downwards in socioeconomic class 12 and end up living in disadvantaged neighborhoods where high calorie food is more affordable than low calorie food and where there are few opportunities for physical activity and energy expenditure. The neighborhoods in which people with schizophrenia live are crowded, violent, and dangerous 13, discouraging residents from even stepping outside the home, never mind walking or jogging 14. In addition, ‘negative’ symptoms such as apathy and asociability are characteristic of approximately 60% of individuals with schizophrenia, which means that people with this diagnosis prefer lonely, sedentary activity such as napping or watching TV to engaging in more vigorous weight-losing activities, especially when these involve other people 15, 16, 17. One study found that 81% of time spent by people with schizophrenia was sedentary time 17.

Twenty-five percent of people with schizophrenia are said to be depressed 18, which makes a passive, isolated, obesity-prone lifestyle even more likely. In order, perhaps, to stay away as much as possible from other people, patients with schizophrenia may reverse day and night, sleep during the day and, at night, have little to do but eat 19.

Another factor is alcohol. Forty percent of men with schizophrenia and 23% of women patients are addicted to alcohol, usually in the form of beer, which is particularly calorigenic 20. More than 60% smoke heavily 21 and when they stop (smoking cessation programs are part of comprehensive care for patients with schizophrenia), they gain weight 22.

Although nutrition guidance is also part of comprehensive treatment, the low calorie diets recommended by dieticians are not only unaffordable but, in addition, require more preparation than ready-made food – a culinary effort that is difficult for people with severe psychotic symptoms to undertake. Despite guidance, patients with schizophrenia continue to eat fatty foods, few fruit and little fiber 23, 24, 25.

Genetic Risk Factors

In recent years, it has been recognized that the same genes may confer risk to different diseases. For instance, for most gene regions that have been linked to schizophrenia, overlapping regions of linkage have also been obtained in type 2 diabetes 26. Understanding copy number variations (CNVs) in the genome has opened up new mechanisms by which a genetic variation can affect more than one phenotype. In the last 5 years, an increasing number of studies have found that individuals who have micro-duplications at the 600-kilobase break points 4 and 5 near the middle of chromosome 16, at a location designated p11.2, have an increased risk of psychotic disorders 27. A meta-analysis reports a fourteen fold-increased risk of psychosis and a sixteen fold increased risk of schizophrenia in individuals with micro-duplication at proximal 16p11.2 28. These same CNVs are associated with decreased body mass while microdeletions in this region are associated with obesity 29.

This is an interesting association between schizophrenia and asthenic build and suggests that it is probably not genetics that makes individuals with schizophreniatend toward obesity but, rather, lifestyle and the medication they take.

Many attempts have been made to look for genes that predispose to antipsychotic-associated weight gain 30, and that work continues.

Treatment Risk Factors

There is little doubt that antipsychotic drugs are critical factors in the current widespread tendency to obesity of schizophrenia patients. A study of 51 patients with chronic schizophrenia who had never received antipsychotic drug treatment and 51 healthy comparison subjects showed that, despite the lifestyle issues referred to above, the drug-naive patients in the study had a significantly lower BMI (19.4) than the controls (22.7) 31. The authors of this study concluded that schizophrenia in the absence of antipsychotic drug treatment is not associated with obesity. The fact remains that almost all individuals diagnosed with schizophrenia do need to be treated with antipsychotic medication and essentially all antipsychotic medications increase weight 32, although some of the many available drugs have been more implicated than others 33, 34, 35, 36. Large appetite increases are sometimes described.


The symptoms of a young male patient with severe schizophrenia improved remarkably when he was changed from a first generation depot antipsychotic to olanzapine 20 mg HS. He had been extremely emaciated (weighing 110 pounds) and apathetic, but, in two months, lost many of his psychotic symptoms, gained twenty pounds and become more active, riding his bicycle everyday. A few months after starting olanzapine, he missed his psychiatric appointment, calling in to explain from a surgical ward of a nearby hospital that he had broken his leg falling off his bike. “I get so terribly hungry,” he said, “that I fell off because I was rushing home – I just couldn’t wait to get something to eat.”

Antipsychotics are not the only psychotropic medications that induce weight gain. As mentioned earlier, many people with schizophrenia suffer from co-morbid depression 18 for which they are commonly treated with antidepressants and mood stabilizers, which also have weight-inducing potential 37.

Other Potential Risks for Obesity in Schizophrenia

Circadian Rhythm Impairment

Circadian rhythms are responsible for daily food intake, hunger and satiety being under the control of a central pacemaker in the anterior hypothalamus. The core clock mechanism is linked to lipogenic and adipogenic pathways so that disruption of circadian physiology can lead to obesity by shifting food intake schedules 38, 39. Meal times are potent synchronizers of biological clocks and the disrupted food intake of people with schizophrenia can be a cause (or a result) of disturbed rhythms 38, 39.

Recent studies have shown that significant sleep/circadian disruption occurs in many if not most patients with schizophrenia 40, 41, 42, 43. The disturbed sleep and lack of routines in eating predispose individuals with schizophrenia to disrupted lipid control that can lead to weight gain and obesity.

Immune Factors

Immune mechanisms can lead to disturbances in glucose metabolism and in inflammatory response that can result in obesity, and this is of potential significance in schizophrenia 44, 45 because the most consistent association in genome-wide association studies (GWAS) of schizophrenia has been with the major histocompatibility complex (MHC) region of the genome, which contains hundreds of genes involved in immunity 46, 47. There may be an active connection in schizophrenia patients between obesity and altered immunity.

Sequelae of Obesity

The negative health consequences of high BMI are mediated by raised blood pressure, disturbances in glucose metabolism, and adverse lipid profiles 48.

Obesity constitutes a major risk factor for type 2 diabetes, to which people with schizophrenia seem particularly prone (see genetic factors above). It has been found that, even in first-episode, drug-naïve patients with schizophrenia, 15% show impaired fasting glucose tolerance, are more insulin resistant and have higher levels of plasma glucose, insulin, and cortisol than healthy comparison subjects. This may be due to shared predisposing genes between schizophrenia and diabetes, or to the stress inherent in this illness 49.

Obesity is a major factor in the metabolic syndrome 50, 51 and in cardiovascular problems 52, which considerably shorten the lives of people with schizophrenia 53. Besides medical problems such as diabetes and metabolic syndrome and cardiovascular problems, obesity poses a risk for sleep apnea and impairs the quality of sleep 54, 55. Obesity increases the risk of respiratory difficulties and, in women, leads to difficult pregnancy and labor. Obesity lowers the threshold for the development of many cancers through the secretion of estrogens, adipokines and cytokines by adipose tissue 56.

There are also psychosocial sequelae of obesity in this population, for instance non-adherence to antipsychotic medication (in an attempt to prevent more weight gain), which can lead to symptomatic relapse and rehospitalization 57. There also appears to be an unexplained positive correlation between obesity and impairment of neurocognitive function in schizophrenia 58, 59. Obesity further impairs quality of life through increased physical and psychological problems as well as increased perceived stigma 60, 61, 62.


One young woman with schizophrenia lived with a boyfriend who came from a well-to-do family. Because she herself was alienated from her family and had essentially no close friends other than her partner, she especially looked forward to holidays when she was invited to her boyfriend’s family’s lavish parties. Her illness symptoms were stable, but, over time, she put on increasing amounts of weight. Her weight soared to 300 pounds and her boyfriend’s family, who had previously been very fond of her, stopped inviting her to parties – they told her boyfriend that they were ashamed for their other guests to see her.

Management of Obesity in Schizophrenia

The management of weight gain and obesity in patients with schizophrenia requires regular and frequent monitoring, early recognition, and multidisciplinary treatment 63.

The strategies are essentially the same as they are in the general population 64, with the added provisos that attempts at health promotion often do not reach this socially isolated population, that psychiatric patients may not regularly see a primary care provider for health screening and monitoring, that the motivation to change is low in this population, and that control of psychotic symptoms usually takes precedence, for both doctor and patient, over the need to keep weight down 65, 66, 67.

Health Promotion

There needs to be an emphasis on prevention through health promotion programs that focus on weight gain and its sequelae and on the urgency of tackling these issues early before metabolic changes ensue. This needs to be started in early intervention for psychosis programs 68 although clinicians are loath to do so for fear of turning patients away from much needed medications. Health promotion for this population needs to be targeted and tailored 69, embedded in healthy life style education that includes diet, exercise, and discontinuation of use of cigarettes and street drugs 70. Despite the significant weight gain that comes after successful smoking cessation and the increase in diabetes and hypertension that comes with it, it remains of primary importance for patients with schizophrenia to stop smoking as this significantly decreases cardiovascular risk, the major factor in the high mortality rate in this population 71.

Screening and Monitoring

Screening and monitoring (waist circumference measures, weight, blood pressure, hemoglobin A1C) have to be conducted regularly and frequently 69, 72, starting with first contact with psychiatric services.

Motivational Interviewing

Motivational interviewing to help motivate patients to change their behavior has been shown to be successful in schizophrenia with respect to weight reduction 73, 74. It is a method that uses open-ended questioning and reflective statements that establish an empathic relationship between patient and counselor. Ambivalences and barriers to change are explored, personal feelings and opinions are solicited, up-to-date information is offered and, as a result, the motivation for change is facilitated. The approach is personalized so that preferences in foods and activities are emphasized 65, 75, 76.


The patient referred to above who was disinvited from her boyfriend’s family’s parties, refused to attend exercise programs because they were “too much work.” She loved dancing, however, and was happy to join a salsa class, which she attended regularly.

Personalized Behavioral Interventions

Behavioral interventions targeting calorie restriction (avoidance of high carbohydrate and high fat foods) and energy output (walking 20-30 minutes a day) work 77, 78, 79, but they need to be personalized, with frequent face-to-face contact. And the providers need to be well trained 80.

Sleep Hygiene

Because disrupted sleep contributes to weight gain, assuring sound sleep helps to combat obesity. Through its effects on circadian rhythms, or perhaps through other means of action, melatonin not only attenuates weight gain but also protects against metabolic syndrome in schizophrenia 81, 82, 83.

Somewhat paradoxically, the weight-inducing drugs used to treat schizophrenia also tend to induce sedation, so that the results of drug switching are never certain.


A young man with a schizophrenia diagnosis had been treated with olanzapine and had put on weight. For this reason, he was switched to aripiprazole, an antipsychotic drug that is a partial agonist and purported to help patients lose weight 84, 85 Unexpectedly, the patient gained even more weight. At the same time, his psychotic symptoms worsened so he was eventually placed on clozapine, a drug for non-responders, which is known to add weight. Paradoxically, he not only stopped gaining weight, but dropped thirty pounds in the ensuing six months. Apparently, while on aripiprazole, the patient had been up in the night eating whereas clozapine, which is sedative, made him sleep through the night.

Medication Changes

Switching from a weight-inducing antipsychotic to one that is relatively weight-sparing is a common clinical strategy, but it is of uncertain benefit 86, 87. Perhaps more important is to keep doses as low as possible and to avoid using more than one antipsychotic medication at a time. Adding metformin is another potentially useful strategy 63, 88, 89.

Prenatal Care

Good prenatal care is critical in schizophrenia because of the potential effects of pregnancy on a genetically-at-risk fetus. Obesity during pregnancy is not uncommon in this population for all the reasons addressed earlier in this paper. Obesity during pregnancy leads to increased rates of gestational diabetes, pre-eclampsia, and difficult labors. Infants are at relatively high risk for congenital malformation and stillbirth. Mothers may experience post-partum hemorrhage. Children of obese mothers may, in later years, develop obesity and metabolic problems 90, 91. Specific dietary advice is, therefore, required, during prenatal care and efforts made to ensure motivation to curb appetite and increase activity levels.


For gross obesity, bariatric surgery is a possibility. It was initially withheld from patients with schizophrenia because it was not known if these patients would be able to manage postsurgical protocols. More recently, it has been found that the success rate of bariatric surgery for people with schizophrenia is the same as it is in the general population 92, 93.

Peer to Peer Support

Peer support and counseling have become part of standard care for schizophrenia on the assumption that individuals are most likely to change behavior if they identify with the counselor. Advice from peers who have gone through similar experiences can sound more credible than advice coming from health care providers. Peers who have experienced and overcome weight gain while maintained on the same medication as the person they are advising can be very powerful role models 94, 95, 96, 97.

Self-Management Programs

Whoever is providing advice, support, and encouragement, in the end, patients must be engaged in their own health care and learn to manage their own weight 98. This holds true for patients with schizophrenia, but this population faces barriers to self-management that are greater than the difficulties faced by patients with other diagnoses. Certain symptoms of schizophrenia – apathy, social isolation, paranoia for example - make it difficult to engage patients in self-care. Schizophrenia patients also have knowledge barriers that can be attributed not only to isolation but also to cognitive deficits. They may be addicted to alcohol or drugs, which cloud consciousness and diminish motivation. The obesity may be of such magnitude that it poses functional barriers to activity of all sorts. Patients with schizophrenia often lack the support of friends and family and they may not be able to sustain good relationships with health care providers 99.Nevertheless, it is possible for patients with schizophrenia to be motivated to take charge of both their physical and their mental health 100.

Technology (Internet programs, email messaging, smart phones, use of pedometers) has proven very useful in the field of self-management 101, 102, 103, 104. And people with schizophrenia have shown that they are not averse to using technology 105, 106.

In many ways, it is more comfortable for many people with this diagnosis to interact with an appliance than with a person 107, 108. Miller et al. 109 found that, at the time their survey was done, 56% of their study participants, all diagnosed with schizophrenia, were using text messaging; 48% had an email account. Twenty seven percent used social media sites daily (Facebook being the most popular) and most of those who used the technology claimed that it increased their ability to socialize.

Treating Obesity in Schizophrenia

Start early to promote health

Use motivational interview techniques

Help with budget, meal planning

Promote abstinence from alcohol, drugs, cigarettes

Offer personalized choices of activity

Provide peer support

Screen and monitor regularly – weight, waist circumference, blood pressure

Address sleep problems

Keep antipsychotic dose low

Consider switching antipsychotics

Avoid polypharmacy

Consider adjunctive metformin

Promote self-management skills

Use technology where appropriate

Target pregnancy in women

Consider surgery for severe obesity


This brief review of the recent literature on obesity and its management in the context of schizophrenic illness has considered risk factors, sequelae, and intervention strategies. A barrier to prevention has been the concern that fears about gaining weight might stop individuals with schizophrenia from taking their antipsychotic medication, a major risk factor for obesity. A holistic approach keeps the dose of antipsychotic medication as low as possible, avoids polypharmacy, encourages healthy eating and physical activity, addresses sleep problems and substance use, monitors weight, blood pressure, and metabolic parameters, makes use of motivational interviewing techniques and peer support, takes special care with reproductive age women and their pregnancies, and seriously considers bariatric surgery for severe obesity. Most importantly, a holistic approach encourages and supports self-management of both physical and mental health.


  1. 1.Kretschmer E. (1925) Physique and Character. AccessedMay18,2016
  1. 2.Zammit S, Rasmussen F, Farahmand B, Gunnell D, Lewis G. (2007) Height and body mass index in young adulthood and risk of schizophrenia: a longitudinal study of 1 347 520 Swedish men. , Acta Psychiatr. Scand 116, 378-385.
  1. 3.D B Allison, J W Newcomer, A L Dunn, J A Blumenthal, A N Fabricatore. (2009) Obesity among those with mental disorders: a National Institute of Mental Health meeting report. , Am. J. Prev. Med 36, 341-350.
  1. 4.T A Ban. (2007) Fifty years chlorpromazine: a historical perspective. , Neuropsychiatr. Dis. Treat 3, 495-500.
  1. 5.H A Nasrallah. (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. , Mol. Psychiatry 13, 27-35.
  1. 6.Coodin S. (2001) Body mass index in persons with schizophrenia. , Can. J. Psychiatry 46, 549-555.
  1. 7.Faulkner G, Cohn T, Remington G, Irving H. (2007) Body mass index, waist circumference and quality of life in individuals with schizophrenia. , Schizophr. Res 90, 174-178.
  1. 8.Ng M, Fleming T, Robinson M, Thomson B, Graetz N. (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study2013. , Lancet 384, 766-781.
  1. 9.Stubbs B, Williams J, F P Gaughran, Craig T K J. (2016) How sedentary are people with psychosis? A systematic review and meta-analysis. doi: 10.1016/j.schres.2016.01.034.
  1. 10. (2016) NCD Risk Factor Collaboration. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. , Lancet 387, 1377-1396.
  1. 11.Ljungqvist I, Topor A, Forssell H, Svensson I, Davidson L. (2015) Money and mental illness: A study of the relationship between poverty and serious psychological problems. , Comm. Ment. Health J 3, 1-9.
  1. 12.E J Costello, S N Compton, Keeler G, Angold A. (2003) Relationships between poverty and psychopathology: A natural experiment. , J.A.M.A 290, 2023-2029.
  1. 13.Roux Diez, V A, Mair C. (2010) Neighborhoods and health. , Ann. N.Y. Acad. Sci 1186, 125-145.
  1. 14.Vancampfort D, M De Hert, A De Hert, K V Bosch, Soundy A. (2013) Associations between physical activity and the built environment in patients with schizophrenia: a multi-centre study. , Gen. Hosp. Psychiatry 35, 653-658.
  1. 15.Brown S, Birtwistle J, Roe L, Thompson C. (1999) The unhealthy lifestyle of people with schizophrenia. , Psychol. Med 29, 697-701.
  1. 16.C A Janney, Ganguli R, C R Richardson, R G Holleman, Tang G. (2013) Sedentary behavior and psychiatric symptoms in overweight and obese adults with schizophrenia and schizoaffective disorders. , (WAIST Study). Schizophr. Res 145, 63-68.
  1. 17.C A Janney, Ganguli R, Tang G, J A Cauley, R G Holleman. (2015) Physical activity and sedentary behavior measured objectively and subjectively in overweight and obese adults with schizophrenia or schizoaffective disorders. , J. Clin. Psychiatry 76, 1277-1284.
  1. 18.V A Chouinard, S M Pingali, Chouinard G, D C Henderson, S G Mallya. (2016) Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders. Psychiatry Res. 237, 304-310.
  1. 19.L B Palmese, J C Ratliff, E L Reutenauer, K M Tonizzo, C M Grilo. (2013) Prevalence of night eating in obese individuals with schizophrenia and schizoaffective disorder. , Compre. Psychiatry 54, 276-281.
  1. 20.Fritz-Wieacker A, Matschinger H, Heider D, Schindler J, Riedel-Heller S. (2007) Health habits of patients with schizophrenia. , Soc. Psychiatry Psychiatr. Epidemiol 42, 268-276.
  1. 21.Paton C, Esop R, Young C, Taylor D. (2004) Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. , Acta Psychiatr. Scand 110, 299-305.
  1. 22.Pistelli F, Aquilini F, Carrozzi L. (2016) Weight gain after smoking cessation. Monaldi Arch. Chest Dis. 71, 81-87.
  1. 23.Dipasquale S, C M Pariante, Dazzan P, Aguglia E, McGuire P. (2013) The dietary pattern of patients with schizophrenia: a systematic review. , J Psychiatr Res 47, 197-207.
  1. 24.D C Henderson, C P Borba, T B Daley, Boxill R, Nguyen D D. (2006) Dietary intake profile of patients with schizophrenia. , Ann. Clin. Psychiatry 18, 99-105.
  1. 25.Tsuruga K, Sugawara N, Sato Y, Saito M, Furukori H. (2015) Dietary patterns and schizophrenia: a comparison with healthy controls. , Neuropsychiatr. Dis. Treat 11, 1115-1120.
  1. 26.Gough S C L, M C O’Donovan. (2005) Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J.Psychopharmacol;19(6Suppl):. 47-55.
  1. 27.A M Maillard, Ruef A, Pizzagalli F, Migliavacca E, Hippolyte L. (2015) The 16p11. 2 locus modulates brain structures common to autism, schizophrenia and obesity. , Mol. Psychiatry 20, 140-147.
  1. 28.Giaroli G, Bass N, Strydom A, Rantell K, McQuillin A. (2014) Does rare matter? Copy number variants at 16p11.2 and the risk of psychosis: a systematic review of literature and meta-analysis. , Schizophr. Res 159, 340-346.
  1. 29.D’Angelo D, Lebon S, Chen Q, Martin-Brevet S, Green Snyder L. (2016) Defining the effect of the 16p11.2 duplication on cognition, behavior, and medical comorbidities. , J.A.M.A. Psychiatry; 73, 20-30.
  1. 30.Ryu S, I S Huh, E Y Cho, Cho Y, Park T. (2016) Association study of 60 candidate genes with antipsychotic-induced weight gain in schizophrenia patients. , Pharmacopsychiatry 49, 51-56.
  1. 31.Padmavati R, R G McCreadie, Tirupati S. (2010) Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. , Schizophr. Res 121, 199-202.
  1. 32.Bak M, Fransen A, Janssen J, J van Os, Drukker M. (2014) Almost all antipsychotics result in weight gain: a meta-analysis. , PloS One 9, 94112.
  1. 33.Correll C U, Lencz T, A K Malhotra. (2011) Antipsychotic drugs and obesity. Trends Mol. , Med 17, 97-107.
  1. 34.M De Hert, Yu W, Detraux J, Sweers K, R van Winkel. (2012) Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder. , C.N.S. Drugs 26, 733-759.
  1. 35.Leucht S, Corves C, Arbter D, Engel R R, Li C. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. , Lancet 373, 31-41.
  1. 36.Parsons B, D B Allison, Loebel A, Williams K, Giller E. (2009) Weight effects associated with antipsychotics: a comprehensive database analysis. , Schizophr. Res 110, 103-110.
  1. 37.D A Wirshing. (2004) Schizophrenia and obesity: impact of antipsychotic medications. , J. Clin. Psychiatry;65(suppl18): 13-26.
  1. 38.Froy O. (2010) Metabolism and circadian rhythms—implications for obesity. , Endoc. Rev 31, 1-24.
  1. 39.Konturek P C, Brzozowski T, Konturek S J. (2011) Gut clock: implication of circadian rhythms in the gastrointestinal tract. , J. Physiol. Pharmacol; 62, 139-150.
  1. 40.Jagannath A, S N Peirson, R G Foster. (2013) Sleep and circadian rhythm disruption in neuropsychiatric illness. , Curr. Opin. Neurobiol 23, 888-894.
  1. 41.J M Monti, A S BaHammam, S R Pandi-Perumal, Bromundt V, D W Spence. (2013) Sleep and circadian rhythm dysregulation in schizophrenia. , Prog. Neuro-Psychopharmacol. Biol. Psychiatry 43, 209-216.
  1. 42.Pritchett D, Wulff K, P L Oliver, D M Bannerman, K E Davies. (2012) Evaluating the links between schizophrenia and sleep and circadian rhythm disruption. , J. Neural Transmiss 119, 1061-1075.
  1. 43.Wulff K, Dijk D J, Middleton B, R G Foster, E M Joyce. (2012) Sleep and circadian rhythm disruption in schizophrenia. , Br. J. Psychiatr 200, 308-316.
  1. 44.M F Gregor, G S Hotamisligil. (2011) Inflammatory mechanisms in obesity. , Ann. Rev. Immunol 29, 415-445.
  1. 45.Steiner J, H G Bernstein, Schiltz K, Müller U J, Westphal S. (2014) Immune system and glucose metabolism interaction in schizophrenia: a chicken–egg dilemma. , Prog. Neuro-Psychopharmacol. Biol. Psychiatry 48, 287-294.
  1. 46.Shi J, D F Levinson, Duan J, A R Sanders, Zheng Y. (2009) Common variants on chromosome 6p22.1 are associated with schizophrenia. , Nature 460, 753-757.
  1. 47.Stefansson H, Ophoff R, Steinberg S, Andreassen O, Cichon S. (2009) Common variants conferring risk of schizophrenia. , Nature 460, 744-747.
  1. 48.Varbo A, Benn M, Davey Smith G, Timpson N J, Tybjaerg-Hansen A. (2015) Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. , Circ. Res 116, 665-673.
  1. 49.Ryan M C M, Collins P, J H Thakore. (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. , Am. J. Psychiatry 160, 284-289.
  1. 50.Malan-Müller S, Kilian S, vandenHeuvel L L, Bardien S, Asmal L. (2016) A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia. , Schizophr. Res 170, 1-7.
  1. 51.J P McEvoy, J M Meyer, D C Goff, H A Nasrallah, S M Davis. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. , Schizophr. Res; 80, 19-32.
  1. 52.L E Rojo, P A Gaspar, Silva H, Risco L, Arena P. (2013) Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. , Psychosom 54, 67-73.
  1. 53.P A Ringen, Engh J, A B Birkenaes, Dieset I, O A Andreassen. (2014) Increased mortality in schizophrenia due to cardiovascular disease-a non-systematic review of epidemiology, possible causes and interventions. , Front. Psychiatry 5, 137.
  1. 54.Myles H, Myles N, N A Antic, Adams R, Chandratilleke M. (2016) Obstructive sleep apnea and schizophrenia: A systematic review to inform clinical practice. , Schizophr. Res 170, 222-225.
  1. 55.J W Winkelman. (2001) Schizophrenia, obesity, and obstructive sleep apnea. , J. Clin. Psychiatry 62, 8-11.
  1. 56.Hsueh W, Deng T. (2016) Obesity,inflammation, cancer. Ann Rev Pathol. Mechanisms Dis. in press;11(1)
  1. 57.Manu P, Khan S, Radhakrishnan R, M J Russ, J M Kane. (2014) Body mass index identified as an independent predictor of psychiatric readmission. , J. Clin. Psychiatry 75, 573-577.
  1. 58.Guo X, Zhang Z, Wei Q, Lv H, Wu R. (2013) The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. , BMC Psychiatry 13, 109.
  1. 59.Rashid N A A, Lim J, Lam M, S A Chong, Keefe R S E. (2013) Unraveling the relationship between obesity, schizophrenia and cognition. , Schizophr. Res 151, 107-112.
  1. 60.R L Kolotkin, P K Corey‐Lisle, R D Crosby, J M Swanson, A V Tuomari. (2008) Impact of obesity on health‐related quality of life in schizophrenia and bipolar disorder. , Obesity 16, 749-754.
  1. 61.Mizock L. (2012) The double stigma of obesity and serious mental illnesses: Promoting health and recovery. , Psychiatr. Rehab. J 35, 466-469.
  1. 62.Strassnig M, J S Brar, Ganguli R. (2003) Body mass index and quality of life in community-dwelling patients with schizophrenia. , Schizophr. Res 62, 73-76.
  1. 63.Manu P, Dima M, Shulman D, Vancampfort D, M De Hert. (2015) Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. , Acta Psychiatr. Scand 132, 97-108.
  1. 64.Jensen M D, Ryan D H, Apovian C M, Ard J D, Comuzzie A G. (2014) 2013AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. , J. Am. Coll. Cardiol 63, 2985-3023.
  1. 65.Caemmerer J, Correll C U, Maayan L. (2012) Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. , Schizophr. Res 140, 159-168.
  1. 66.M De Hert, Bobes J, Cetkovich-Bakmas M. (2011) Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, and recommendations at the system and individual level. World Psychiatry. 10, 138-151.
  1. 67.Hjorth P, A S Davidsen, Kilian R, Skrubbeltrang C. (2014) A systematic review of controlled interventions to reduce overweight and obesity in people with schizophrenia. , Acta Psychiatr. Scand 130, 279-289.
  1. 68.Shiers D, P B Jones, Field S. (2009) Early intervention in psychosis: keeping the body in mind. , Br. J. Gen. Pract 59, 395-396.
  1. 69.A J Mitchell, M De Hert. (2015) Promotion of physical health in persons with schizophrenia: can we prevent cardiometabolic problems before they begin? Acta Psychiatr. , Scand 132, 83-85.
  1. 70.L H Beebe. (2008) Obesity in schizophrenia: screening, monitoring, and health promotion. , Perspect. Psychiatr. Care 44, 25-31.
  1. 71.A N Thorndike, E D Achtyes, Cather C, Pratt S, G N Pachas. (2016) Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial. , J. Clin. Psychiatry 77, 320-326.
  1. 72.S R Marder, S M Essock, A L Miller, R W Buchanan, D E Casey. (2004) Physical health monitoring of patients with schizophrenia. , Am. J. Psychiatry 161, 1334-1349.
  1. 73.S J Bartels, S I Pratt, K A Aschbrenner, L K Barre, Jue K. (2013) Clinically significant improved fitness and weight loss among overweight persons with serious mental illness. , Psychiatr. Serv 64, 729-736.
  1. 74.Niv N, A N Cohen, Hamilton A, Reist C, A S Young. (2014) Effectiveness of a psychosocial weight management program for individuals with schizophrenia. , J. Behav. Health Serv. Res 41, 370-80.
  1. 75.Firth J, Rosenbaum S, Stubbs B, Vancampfort D, Carney R. (2016) Preferences and motivations for exercise in early psychosis. doi: 10.1111/acps.12562. Acta Psychiatr.
  1. 76.Soundy A, Freeman P, Stubbs B, Probst M, Coffee P. (2014) The transcending benefits of physical activity for individuals with schizophrenia: a systematic review and meta-ethnography. Psychiatry Res. 220, 11-19.
  1. 77.Z D Erickson, S J Mena, J M Pierre, L H Blum, Martin E. (2016) Behavioral interventions for antipsychotic medication–associated obesity: A randomized, controlled clinical trial. , J. Clin. Psychiatry 77, 183-189.
  1. 78.Gorczynski P, Faulkner G. (2010) Exercise therapy for schizophrenia. Cochrane Database Syst. , Rev 12, 004412.
  1. 79.Loh C, J M Meyer, S G Leckband. (2006) A comprehensive review of behavioral interventions for weight management in schizophrenia. , Ann. Clin. Psychiatry 18, 23-31.
  1. 80.M C Ward, D T White, B G Druss. (2015) A meta-review of lifestyle interventions for cardiovascular risk factors in the general medical population: lessons for individuals with serious mental illness. , J. Clin. Psychiatry 76, 477-486.
  1. 81.Anderson G, Maes M. (2012) Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. , Metab. Brain Dis 27, 113-119.
  1. 82.Modabbernia A, Heidari P, Soleimani R, Sobhani A, Z A Roshan. (2014) Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: Randomized double-blind placebo-controlled study. , J. Psychiatr. Res 53, 133-140.
  1. 83.Romo‐Nava F, Alvarez‐Icaza González D, Fresán‐Orellana A, Saracco Alvarez R, Becerra‐Palars C. (2014) Melatonin attenuates antipsychotic metabolic effects: an eight‐week randomized, double‐blind, parallel‐group, placebo‐controlled clinical trial. , Bipolar Disord 16, 410-421.
  1. 84.D C Henderson, Fan X, P M Copeland, Sharma B, C P Borba. (2009) Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. , J. Clin. Psychopharmacol 29, 165-168.
  1. 85.J W Newcomer, J A Campos, R N Marcus, Breder C, R M Berman. (2008) A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffectve disorder switched from olanzapine. , J. Clin. Psychiatry 69, 1046-1056.
  1. 86.Mukundan A, Faulkner G, Cohn T, Remington G. (2010) Anti-psychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst. , Rev 12, 006629.
  1. 87.Stroup T S, McEvoy J P, Ring K D, Hamer R H, LaVange L M. (2011) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). , Am. J. Psychiatry 168, 947-956.
  1. 88.Maayan L, Vakhrusheva J, Correll C U. (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. , Neuropsychopharmacol 35, 1520-1530.
  1. 89.Wu R R, J P Zhao, Jin H, Shao P, M S Fang. (2008) Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. , J.A.M.A 299, 185-193.
  1. 90.Poston L, L F Harthoorn, E M vanderBeek. (2011) Obesity in pregnancy: implications for the mother and lifelong health of the child. A consensus statement. , Pediatr. Res 69, 175-180.
  1. 91.Tsoi E, Shaikh H, Robinson S, T G. (2010) Obesity in pregnancy: a major healthcare issue. , Postgrad. Med. J 86, 617-623.
  1. 92.H F Fuchs, Laughter V, C R Harnsberger, R C Broderick, Berducci M. (2016) Patients with psychiatric comorbidity can safely undergo bariatric surgery with equivalent success. , Surg. Endosc 30, 251-258.
  1. 93.Hamoui N, Kingsbury S, G J Anthone, P F Crookes. (2004) Surgical treatment of morbid obesity in schizophrenic patients. , Obes. Surg 14, 349-352.
  1. 94.Davidson L, Chinman M, Kloos B, Weingarten R, Stayner D. (1999) Peer support among individuals with severe mental illness: A review of the evidence. , Clin. Psychol. Sci. Pract 6, 165-187.
  1. 95.Lucksted A, McNulty K, Brayboy L, Forbes C. (2015) Initial evaluation of the Peer-to-Peer program. , Psychiatr. Serv 60, 250-253.
  1. 96.J A Naslund, K A Aschbrenner, L A Marsch, S J Bartels. (2016) The future of mental health care: peer-to-peer support and social media. , Epidemiol. Psychiatr. Sci 8, 1-0.
  1. 97.Rummel-Kluge C, Stiegler-Kotzor M, Schwarz C, W P Hansen, Kissling W. (2008) Peer-counseling in schizophrenia: patients consult patients. Patient Educ. , Couns 70, 357-362.
  1. 98.Greene J, J H Hibbard. (2012) Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. , J. Gen. Intern. Med 27, 520-526.
  1. 99.C E Blixen, Kanuch A, A T Perzynski, Thomas C, N V Dawson. (2016) Barriers to self-management of serious mental illness and diabetes. , Am. J. Health Behav 40, 194-204.
  1. 100.R W Goldberg, Dickerson F, Lucksted A, C H Brown, Weber E. (2013) Living well: an intervention to improve self-management of medical illness for individuals with serious mental illness. , Psychiatr. Serv 64, 51-57.
  1. 101.K A Aschbrenner, J A Naslund, L E Gill, S J Bartels, Ben-Zeev D. (2016) A qualitative study of client-clinician text exchanges in a mobile health intervention for individuals with psychotic disorders and substance use. , J. Dual Diagn 12, 63-71.
  1. 102.L H Beebe, R F Harris. (2012) Using pedometers to document physical activity in patients with schizophrenia spectrum disorders: a feasibility study. , J. Psychosoc. Nurs. Ment. Health Serv 50, 44-49.
  1. 103.Ben-Zeev D, S M Kaiser, C J Brenner, Begale M, Duffecy J. (2013) Development and usability testing of FOCUS: A smartphone system for self-management of schizophrenia. , Psychiatr. Rehab. J 36, 289-296.
  1. 104.Gaebel W, Großimlinghaus I, Kerst A, Cohen Y, Hinsche-Böckenholt A. (2016) European Psychiatric Association (EPA) guidance on the quality of eMental health interventions in the treatment of psychotic disorders. , Eur. Arch. Psychiatry Clin. Neurosci 266, 125-137.
  1. 105.Firth J, Cotter J, Torous J, Bucci S, J A Firth. (2016) Mobile phone ownership and endorsement of “mhealth” among people with psychosis: A meta-analysis of cross-sectional studies. , Schizophr. Bull 42, 448-455.
  1. 106.Schrank B, Sibitz I, Unger A, Amering M. (2010) How patients with schizophrenia use the internet: qualitative study. , J. Med. Internet Res 12, 70.
  1. 107.Ben-Zeev D, C J Brenner, Begale M, Duffecy J, D C Mohr. (2014) Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. , Schizophr. Bull 40, 1244-1253.
  1. 108.Firth J, Torous J. (2015) Smartphone apps for schizophrenia: a systematic review. , JMIR mHealth uHealth 3, 102.
  1. 109.B J Miller, Stewart A, Schrimsher J, Peeples D, P F Buckley. (2015) How connected are people with schizophrenia? Cell phone, computer, email, and social media use. , Psychiatr. Res 225, 458-463.

Cited by (5)

  1. 1.GEZGİN YAZICI Havva, ŞAHİNER İsmail Volkan, DİDİN Müşerref, ÖNER Sevde, 2022, Weight Gain, Mental Symptoms and Self-Esteem in Patients with Schizophrenia, Psikiyatride Güncel Yaklaşımlar, 14(Ek 1), 100, 10.18863/pgy.1113719
  1. 2.Seeman Mary V., 2021, Sex differences in schizophrenia relevant to clinical care, Expert Review of Neurotherapeutics, 21(4), 443, 10.1080/14737175.2021.1898947
  1. 3.Seeman Mary V., 2020, Men and women respond differently to antipsychotic drugs, Neuropharmacology, 163(), 107631, 10.1016/j.neuropharm.2019.05.008
  1. 4.Speyer Helene, Westergaard Casper, Albert Nikolai, Karlsen Mette, Stürup Anne Emilie, et al, 2021, Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis, Frontiers in Endocrinology, 12(), 10.3389/fendo.2021.577919
  1. 5.Seeman Mary V., González-Rodríguez Alexandre, 2018, Use of psychotropic medication in women with psychotic disorders at menopause and beyond, Current Opinion in Psychiatry, 31(3), 183, 10.1097/YCO.0000000000000410